Drug Trial Radar · NCT03147092
Matão Controlling Hypertension (MatCH Study): Rationale and Design
Last checked: Nov 19, 2026Latest source record: Nov 21, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
15,000
Planned (sponsor's estimate)
Start
Feb 1, 2018
Primary completion
Jun 30, 2020
Study completion Jun 30, 2021
Sponsor
- Lead sponsor
- Centro Neurológico de Pesquisa e Reabiitação, BrazilAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 10, 2017
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Background Hypertension is the main risk factor for most cardiovascular diseases. Blood pressure (BP) control has been shown to reduce the incidence of stroke, myocardial infarction, renal diseases and heart failure. Although BP lowering is effective, few population programs can achieve BP control. A coordinated and organized system from the Brazilian Ministry of Healthy involving Family Health Strategy (FHS), a program for the prevention of chronic disease, and the Popular Pharmacy Program (PPP), which subsidizes medications for the population, could allow an earlier identification and better BP control. Matão Controlling Hypertension (MatCH) is a community-based population project that aims to apply an organized, integrated and coordinated program in the city of Matão, Brazil, involving FSH and PPP in order to actively search, treat and follow-up hypertensive subjects. Method This is a population community-based, prospective, interventional, follow-up study where all subjects aged ≥ 40 years assisted by the FHS program in Matão will have BP assessed monthly by trained Community Health Agents (CHA) during a domiciliary visit. Identified hypertensive subjects will be referred to FHS physicians for nonpharmacological and pharmacological treatment. Most of the hypertensive drugs used will be available thought the PPP. Prevalence of hypertension, awareness, demographics and risk factors will be correlated with BP control. The population study is expected to involve approximately 15,000 subjects. The study period will be four years. Discussion Considering that hypertension is asymptomatic in most cases, to reduce the population burden of BP-related deaths and diseases it is essential to detect and treat early all hypertensive patients. If BP control be achieved on a large scale, this program can be applied to other populations from developing countries.
Conditions
- Hypertension
- Blood Pressure
Interventions
Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet,Drug
Treatment of hypertensive subjects
AtenololDrug
Treatment of hypertensive subjects
Losartan potassium 50mgDrug
Treatment of hypertensive subjects
ClonidineDrug
Treatment of hypertensive subjects
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of hypertensive subjects with BP controlled during follow-upTime frame: Through study completion, an average of 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.